Missed symptoms of menopause

International Journal of Clinical Practice

Volumn 61, Issue 12, 2007, Pages 2041-2050

  Warren, M P ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DULOXETINE; ESCITALOPRAM; ESTROGEN; FLUOXETINE; FLUVOXAMINE; GESTAGEN; MILNACIPRAN; NORADRENALIN; PAROXETINE; PLACEBO; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

CLIMACTERIUM; CLINICAL TRIAL; DECREASED APPETITE; DRUG EFFICACY; ETHNIC GROUP; HORMONAL THERAPY; HORMONE DETERMINATION; HOT FLUSH; HUMAN; INSOMNIA; MENOPAUSAL SYNDROME; MENSTRUATION; MOOD CHANGE; MOOD DISORDER; NAUSEA; NIGHT SWEAT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SLEEP DISORDER; TREATMENT OUTCOME; XEROSTOMIA;

CLIMACTERIC; DIAGNOSTIC ERRORS; FEMALE; HUMANS; MOOD DISORDERS; SEROTONIN UPTAKE INHIBITORS; SLEEP DISORDERS;

EID: 35948932115     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01566.x     Document Type: Review

References (79)

1. National Institutes of Health. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med 2005 142 : 1003 13.
2. Guthrie JR, Dennerstein L, Taffe JR et al. Health care-seeking for menopausal problems. Climacteric 2003 6 : 112 7.
3. Klaiber EL, Broverman DM, Vogel W et al. Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry 1979 36 : 550 4.
4. Studd J, Versi E, Watson N et al. Management of the menopause. Lancet 1993 342 : 553 4.
5. Studd J, Panay N. Hormones and depression in women. Climacteric 2004 7 : 338 46.
6. Woods NF, Mitchell ES. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives. Am J Med 2005 118 : 14 24.
7. Gold EB, Block G, Crawford S et al. Lifestyle and demographic factors in relation to vasomotor symptoms: baseline results from the Study of Women's Health Across the Nation. Am J Epidemiol 2004 159 : 1189 99.
8. Kravitz HM, Ganz PA, Bromberger J et al. Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition. Menopause 2003 10 : 19 28.
9. Avis NE, Brockwell S, Colvin A. A universal menopausal syndrome? Am J Med 2005 118 : 37 46.
10. Mishra G, Lee C, Brown W et al. Menopausal transitions, symptoms and country of birth: the Australian Longitudinal Study on Women's Health. Aust N Z J Public Health 2002 26 : 563 70.
11. Goonaratna C, Fonseka P, Wijeywardene K. Perimenopausal symptoms in Sri Lankan women. Ceylon Med J 1999 44 : 63 9.
12. Bener A, Rizk DE, Shaheen H et al. Measurement-specific quality-of-life satisfaction during the menopause in an Arabian Gulf country. Climacteric 2000 3 : 43 9.
13. Aaron R, Muliyil J, Abraham S. Medico-social dimensions of menopause: a cross-sectional study from rural south India. Natl Med J India 2002 15 : 14 7.
14. Porter M, Penney GC, Russell D et al. A population based survey of women's experience of the menopause. Br J Obstet Gynaecol 1996 103 : 1025 8.
15. Obermeyer CM, Reher D, Alcala LC et al. The menopause in Spain: results of the DAMES (Decisions At MEnopause) Study. Maturitas 2005 52 : 190 8.
16. Obermeyer CM, Schulein M, Hajji N et al. Menopause in Morocco: symptomatology and medical management. Maturitas 2002 41 : 87 95.
17. Obermeyer CM, Ghorayeb F, Reynolds R. Symptom reporting around the menopause in Beirut, Lebanon. Maturitas 1999 33 : 249 58.
18. Chim H, Tan BH, Ang CC et al. The prevalence of menopausal symptoms in a community in Singapore. Maturitas 2002 41 : 275 82.
19. Bachmann GA. Menopausal vasomotor symptoms. A review of causes, effects and evidence-based treatment options. J Reprod Med 2005 50 : 155 65.
20. Mom CH, Buijs C, Willemse PH et al. Hot flushes in breast cancer patients. Crit Rev Oncol Hematol 2006 57 : 63 77.
21. North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004 11 : 11 33.
22. Maclennan AH, Broadbent JL, Lester S et al. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004 CD002978.
23. Cohen LS, Soares CN, Vitonis AF et al. Risk for new onset of depression during the menopausal transition: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry 2006 63 : 385 90.
24. Freeman EW, Sammel MD, Lin H et al. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006 63 : 375 82.
25. Dennerstein L, Burrows GD, Hyman GJ et al. Hormone therapy and affect. Maturitas 1979 1 : 247 59.
26. Polo-Kantola P, Erkkola R, Helenius H et al. When does estrogen replacement therapy improve sleep quality? Am J Obstet Gynecol 1998 178 : 1002 9.
27. Soares CN, Almeida OP, Joffe H et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001 58 : 529 34.
28. Barnabei VM, Grady D, Stovall DW et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 2002 100 : 1209 18.
29. Vestergaard P, Hermann AP, Stilgren L et al. Effects of 5 years of hormonal replacement therapy on menopausal symptoms and blood pressure - a randomised controlled study. Maturitas 2003 46 : 123 32.
30. Saletu B. Sleep, vigilance and cognition in postmenopausal women: placebo-controlled studies with 2 mg estradiol valerate, with and without 3 mg dienogest. Climacteric 2003 6 (Suppl. 2 37 45.
31. Schurmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 2004 7 : 189 96.
32. Barnabei VM, Cochrane BB, Aragaki AK et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 2005 105 : 1063 73.
33. Nielsen TF, Ravn P, Pitkin J et al. Pulsed estrogen therapy improves postmenopausal quality of life: a 2-year placebo-controlled study. Maturitas 2006 53 : 184 90.
34. Brunner RL, Gass M, Aragaki A et al. Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial. Arch Intern Med 2005 165 : 1976 86.
35. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004 291 : 47 53.
36. Randolph JF Jr., Sowers M, Bondarenko I et al. The relationship of longitudinal change in reproductive hormones and vasomotor symptoms during the menopausal transition. J Clin Endocrinol Metab 2005 90 : 6106 12.
37. Freedman RR. Physiology of hot flashes. Am J Hum Biol 2001 13 : 453 64.
38. Berendsen HH. The role of serotonin in hot flushes. Maturitas 2000 36 : 155 64.
39. Deecher DC. Physiology of thermoregulatory dysfunction and current approaches to the treatment of vasomotor symptoms. Expert Opin Investig Drugs 2005 14 : 435 48.
40. Kimmick GG, Lovato J, McQuellon R et al. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J 2006 12 : 114 22.
41. Loprinzi CL, Sloan JA, Perez EA et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002 20 : 1578 83.
42. Stearns V, Beebe KL, Iyengar M et al. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003 289 : 2827 34.
43. Stearns V, Slack R, Greep N et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005 23 : 6919 30.
44. Nemeroff CB, Owens MJ. Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis. CNS Spectr 2004 9 : 23 31.
45. Loprinzi CL, Kugler JW, Sloan JA et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000 356 : 2059 63.
46. Siegel JM. The neurotransmitters of sleep. J Clin Psychiatry 2004 65 (Suppl. 16 4 7.
47. Delgado PL. Common pathways of depression and pain. J Clin Psychiatry 2004 65 (Suppl. 12 16 9.
48. Grothe DR, Scheckner B, Albano D. Treatment of pain syndromes with venlafaxine. Pharmacotherapy 2004 24 : 621 9.
49. Culpepper L. Generalized anxiety disorder in primary care: emerging issues in management and treatment. J Clin Psychiatry 2002 63 (Suppl. 8 35 42.
50. Shelton RC. The dual-action hypothesis: does pharmacology matter? J Clin Psychiatry 2004 65 (Suppl. 17 5 10.
51. Fava M. Somatic symptoms, depression, and antidepressant treatment. J Clin Psychiatry 2002 63 : 305 7.
52. Fava M. The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. J Clin Psychiatry 2003 64 (Suppl. 13 26 9.
53. Barton D, La VB, Loprinzi C et al. Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. Oncol Nurs Forum 2002 29 : 33 40.
54. Suvanto-Luukkonen E, Koivunen R, Sundstrom H et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 2005 12 : 18 26.
55. US Food and Drug Administration. Guidance for Industry. Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms - Recommendations for Clinical Evaluation. Rockville, MD : US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER), 2003.
56. Barton DL, Loprinzi CL, Novotny P et al. Pilot evaluation of citalopram for the relief of hot flashes. J Support Oncol 2003 1 : 47 51.
57. Loprinzi CL, Flynn PJ, Carpenter LA et al. Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine. J Palliat Med 2005 8 : 924 30.
58. Nagata H, Nozaki M, Nakano H. Short-term combinational therapy of low-dose estrogen with selective serotonin re-uptake inhibitor (fluvoxamine) for oophorectomized women with hot flashes and depressive tendencies. J Obstet Gynaecol Res 2005 31 : 107 14.
59. Stearns V, Isaacs C, Rowland J et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000 11 : 17 22.
60. Weitzner MA, Moncello J, Jacobsen PB et al. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manage 2002 23 : 337 45.
61. Biglia N, Torta R, Roagna R et al. Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. Maturitas 2005 52 : 78 85.
62. Grady D, Cohen B, Tice J et al. Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial. Obstet Gynecol 2007 109 : 823 30.
63. Evans ML, Pritts E, Vittinghoff E et al. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005 105 : 161 6.
64. Reame NK. The emerging science of hot flash relief: legitimizing the 'obecalp' effect. Menopause 2005 12 : 4 7.
65. Rudolph I, Palombo-Kinne E, Kirsch B et al. Influence of a continuous combined HRT (2 mg estradiol valerate and 2 mg dienogest) on postmenopausal depression. Climacteric 2004 7 : 301 11.
66. Zweifel JE, O'Brien WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 1997 22 : 189 212.
67. Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 2001 3 : 22 7.
68. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders - III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998 12 : S55 87.
69. Montgomery JC, Appleby L, Brincat M et al. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. Lancet 1987 1 : 297 9.
70. Wyeth Pharmaceuticals Inc. Prempro (Package Insert). Philadelphia, PA : Wyeth Pharmaceuticals Inc., 2006.
71. Cramer EH, Jones P, Keenan NL et al. Is naturopathy as effective as conventional therapy for treatment of menopausal symptoms? J Altern Complement Med 2003 9 : 529 38.
72. Carpenter JS, Neal JG. Other complementary and alternative medicine modalities: acupuncture, magnets, reflexology, and homeopathy. Am J Med 2005 118 : 109 17.
73. Soares CN, Prouty J, Born L et al. Treatment of menopause-related mood disturbances. CNS Spectr 2005 10 : 489 97.
74. Thase ME, Entsuah R, Cantillon M et al. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health (Larchmt) 2005 14 : 609 16.
75. Burt VK, Wohlreich MM, Mallinckrodt CH et al. Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years. Psychosomatics 2005 46 : 345 54.
76. Martenyi F, Dossenbach M, Mraz K et al. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol 2001 11 : 227 32.
77. Grigoriadis S, Kennedy SH, Bagby RM. A comparison of antidepressant response in younger and older women. J Clin Psychopharmacol 2003 23 : 405 7.
78. Pinto-Meza A, Usall J, Serrano-Blanco A et al. Gender differences in response to antidepressant treatment prescribed in primary care. Does menopause make a difference? J Affect Disord 2006 93 : 53 60.
79. Joffe H, Hall JE, Soares CN et al. Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause 2002 9 : 392 8.